Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage
- Sponsor
- Technical University of Munich
- Study ID
- NCT01179529
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Omalizumab (Xolair®) — DRUG
Study Details
This study aims at evaluating the therapeutic potential of omalizumab in atopic dermatitis, and to work out biomarkers predictive of treatment response.
Key Dates
- Status verified
- Jan 2012
Study Design
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Omalizumab
Primary Outcome Measure
To evaluate efficacy of Omalizumab treatment in a sample of adult patients with moderate to severe AD
Related Studies
- Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis ResearchRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Studies of Skin Microbes in Healthy People and in People With Skin ConditionsRecruiting · National Human Genome Research Institute (NHGRI) · Bethesda, Maryland
- Natural History and Genetics of Food Allergy and Related ConditionsRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)Recruiting · Regeneron Pharmaceuticals · Boston, Massachusetts